Sensei Biotherapeutics, Inc. today announced that it has acquired Faeth Therapeutics Inc. (“Faeth”), a clinical-stage biotechnology company developing multi-node therapies that target tumor metabolism and signaling. The acquisition brings Faeth’s lead asset PIKTOR, a proprietary investigational all-oral combination of serabelisib and sapanisertib that inhibits multiple nodes of the PI3K/AKT/mTOR pathway through PI3K-alpha and dual mTORC1/2 targeting, into Sensei’s pipeline..

Sensei Biotherapeutics, Inc. 今天宣布已完成对 Faeth Therapeutics Inc.（“Faeth”）的收购，这是一家临床阶段的生物技术公司，致力于开发针对肿瘤代谢和信号传导的多节点疗法。此次收购将 Faeth 的主要资产 PIKTOR 纳入 Sensei 的研发管线，PIKTOR 是一种专有的研究性全口服组合疗法，包含 serabelisib 和 sapanisertib，通过 PI3K-alpha 和双重 mTORC1/2 靶向抑制 PI3K/AKT/mTOR 通路的多个节点。

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260217234993/en/

本新闻稿包含多媒体。请在此处查看完整发布：https://www.businesswire.com/news/home/20260217234993/en/

Concurrent with the acquisition, Sensei entered into a definitive agreement for the sale of Series B non-voting convertible preferred stock in a private placement financing, which is expected to result in gross proceeds to Sensei of approximately $200 million before deducting placement agent and other offering expenses.

与收购同时，Sensei签订了一项最终协议，出售B系列无投票权可转换优先股，作为私募融资的一部分，预计在扣除配售代理费和其他发行费用之前，Sensei将获得约2亿美元的总收益。

The financing included participation from B Group Capital, Balyasny Asset Management, Columbia Threadneedle Investments, Cormorant Asset Management, Fairmount, Logos Capital, RA Capital Management, Vivo Capital, multiple leading life sciences funds, and other institutional investors. Sensei expects to use the proceeds primarily to advance PIKTOR through key clinical milestones, including topline data from an ongoing Phase 2 trial in second-line advanced endometrial cancer, as well as the initiation of a Phase 1b trial in HR+/HER2- advanced breast cancer, both expected by year end 2026, with remaining proceeds for general corporate purposes and completion of Sensei's ongoing Phase 1/2 trial of solnerstotug..

融资方包括B集团资本、巴利亚斯尼资产管理公司、哥伦比亚Threadneedle投资公司、鸬鹚资产管理公司、费尔蒙特、逻各斯资本、RA资本管理公司、维沃资本、多个领先的生命科学基金以及其他机构投资者。Sensei预计将会把所得款项主要用于推动PIKTOR通过关键的临床里程碑，包括来自正在进行的二线晚期子宫内膜癌二期试验的顶线数据，以及预计在2026年底前启动的HR+/HER2-晚期乳腺癌一期b阶段试验，剩余资金将用于一般公司用途及完成Sensei正在进行的Solnerstotug一期/二期试验。

“The clinical data, the caliber of the scientific team, and the investor syndicate that came together for these transactions reinforce our conviction in the program,” said Bob Holmen, Chairman of the Board of Directors of Sensei Biotherapeutics. “With these proceeds, we believe the company is well capitalized to execute through key clinical milestones in endometrial and breast cancer.”.

“这些交易汇集的临床数据、科学团队的水平以及投资集团，都加强了我们对这个项目的信心，”Sensei Biotherapeutics董事会主席鲍勃·霍尔曼表示。“有了这笔资金，我们相信公司有足够的资本通过子宫内膜癌和乳腺癌的关键临床里程碑。”

“In the PI3K pathway, the field has repeatedly run into the same constraint. Single-node inhibitors force a tradeoff between efficacy and tolerability,” said Anand Parikh, Co-founder of Faeth Therapeutics and new Chief Operating Officer and director of Sensei. “PIKTOR is designed to change that tradeoff by inhibiting PI3K-alpha and mTORC1/2 simultaneously, and we believe we can achieve more complete pathway suppression with improved tolerability.

“在PI3K通路中，领域内反复遇到同一个限制。单节点抑制剂迫使在疗效和耐受性之间做出权衡，”Faeth Therapeutics联合创始人兼Sensei首席运营官及董事Anand Parikh表示。“PIKTOR旨在通过同时抑制PI3K-alpha和mTORC1/2来改变这种权衡，我们相信能够实现更彻底的通路抑制并改善耐受性。”

We saw the signal in our Phase 1b, including a number of complete responses in endometrial cancer patients after multiple prior lines of therapy. This financing takes us through topline Phase 2 data in that population and advances the Phase 1b breast cancer program.”.

我们在1b期试验中看到了信号，包括多线治疗后子宫内膜癌患者的多个完全缓解案例。此次融资将帮助我们获得该人群的2期试验主要数据，并推进1b期乳腺癌项目。

About Sensei Biotherapeutics

关于Sensei Biotherapeutics

Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) is a clinical-stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients. Following the acquisition of Faeth Therapeutics, Sensei's lead program is PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer.

Sensei Biotherapeutics, Inc.（纳斯达克股票代码：SNSE）是一家临床阶段的生物技术公司，专注于为癌症患者发现和开发下一代疗法。在收购Faeth Therapeutics后，Sensei的主要项目是PIKTOR，这是一种正在开发中的PI3K/AKT/mTOR通路多节点抑制剂，用于治疗子宫内膜癌和乳腺癌。

Sensei is also completing a Phase 1/2 trial of solnerstotug, its V-domain Ig suppressor of T cell activation (VISTA) inhibitor, in patients with advanced solid tumors..

Sensei公司也在完成其VISTA抑制剂solnerstotug在晚期实体瘤患者中的1/2期试验，该抑制剂是一种T细胞活化的V结构域Ig抑制剂。

Sensei intends to use its website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. For more information, please visit www.senseibio.com and follow the company on X @SenseiBio and LinkedIn.

Sensei 打算利用其网站作为披露重大非公开信息的手段，并遵守《公平披露规定》下的披露义务。欲了解更多信息，请访问 www.senseibio.com 并在 X @SenseiBio 和 LinkedIn 上关注该公司。

About Faeth Therapeutics

关于Faeth Therapeutics

Faeth Therapeutics is a clinical-stage biotechnology company developing multi-node therapies that target tumor metabolism and signaling. The company’s lead program, PIKTOR, is an investigational all-oral combination of serabelisib and sapanisertib designed to inhibit multiple nodes of the PI3K/AKT/mTOR pathway, including PI3K-alpha and mTORC1/2.

Faeth Therapeutics是一家临床阶段的生物技术公司，致力于开发针对肿瘤代谢和信号传导的多节点疗法。该公司的主要项目PIKTOR是一种研究性全口服组合药物，包含serabelisib和sapanisertib，旨在抑制PI3K/AKT/mTOR通路的多个节点，包括PI3K-alpha和mTORC1/2。

Faeth is advancing PIKTOR across solid tumors, including endometrial and breast cancer..

Faeth正在推进PIKTOR在实体瘤中的应用，包括子宫内膜癌和乳腺癌。

Faeth was co-founded in 2019 by Anand Parikh and Oliver Maddocks, PhD. Faeth’s scientific founders include Lewis Cantley, PhD (discoverer of the PI3K pathway), Siddhartha Mukherjee, MD, DPhil (Pulitzer Prize–winning physician-scientist), Karen Vousden, PhD, Scott Lowe, PhD, and Greg Hannon, PhD.

Faeth 由 Anand Parikh 和 Oliver Maddocks 博士于2019年共同创立。Faeth 的科学创始人包括 Lewis Cantley 博士（PI3K 通路的发现者）、Siddhartha Mukherjee 医学博士、哲学博士（普利策奖获奖医生科学家）、Karen Vousden 博士、Scott Lowe 博士和 Greg Hannon 博士。

About PIKTOR

关于PIKTOR

PIKTOR is a proprietary investigational all-oral combination of serabelisib and sapanisertib that inhibits multiple nodes of the PI3K/AKT/mTOR pathway, including PI3K-alpha and dual mTORC1/2. In a completed Phase 1b trial, PIKTOR plus paclitaxel demonstrated an overall response rate of 47% in response-evaluable patients (n=15) averaging four prior lines of therapy (range 1–12), with a 71% response rate in patients with PI3K pathway mutations, including three complete responses, two in endometrial cancer, with progression-free survival of 26.9 and 20.0 months.

PIKTOR 是一种专有的研究性全口服组合药物，包含 serabelisib 和 sapanisertib，可抑制 PI3K/AKT/mTOR 通路的多个节点，包括 PI3K-alpha 和双重 mTORC1/2。在已完成的 1b 期试验中，PIKTOR 加紫杉醇在可评估反应的患者（n=15）中显示出 47% 的总体缓解率，这些患者平均接受过四线先前治疗（范围 1-12），其中 PI3K 通路突变患者的缓解率达到 71%，包括三例完全缓解，两例为子宫内膜癌，无进展生存期分别为 26.9 个月和 20.0 个月。

PIKTOR is currently being studied in solid tumor settings, including endometrial and breast cancer..

PIKTOR目前正在进行实体瘤研究，包括子宫内膜癌和乳腺癌。

About the Transactions

关于交易

The acquisition of Faeth was structured as a stock-for-stock transaction pursuant to which all of Faeth’s outstanding equity interests were exchanged based on a fixed exchange ratio for a combination of 252,210 shares of Sensei common stock and approximately 10,604 shares of Series B non-voting convertible preferred stock (representing 10,604,490 shares on an as-converted-to-common basis), in each case, calculated on a fully-diluted basis (and without giving effect to any beneficial ownership limitations).

Faeth 的收购被构架为一项股票换股票的交易，根据该交易，Faeth 所有已发行的股权权益均按照固定的兑换比率被交换为 252,210 股 Sensei 普通股和约 10,604 股 B 系列无投票权可转换优先股（在完全摊薄的基础上相当于 10,604,490 股普通股），每种情况均按完全稀释基础计算（且不考虑任何有益所有权限制）。

Concurrently with the acquisition of Faeth, Sensei entered into a definitive agreement for a private placement financing with new and returning investors to raise $200 million in which the investors will be issued approximately 14,440 shares of Series B non-voting convertible preferred stock (or 14,440,395 on an as-converted-to-common basis and without giving effect to any beneficial ownership limitations) at a price of approximately $13,850 per share (or approximately $13.85 per share on an as-converted-to-common basis).

同时，在收购Faeth的过程中，Sensei与新老投资者签订了一项确定的私人配售融资协议，计划筹集2亿美元。根据协议，投资者将获得约14,440股B系列非投票可转换优先股（或在转换为普通股的基础上，不考虑任何有益所有权限制的情况下，约为14,440,395股），每股价格约为13,850美元（或在转换为普通股的基础上，每股价格约为13.85美元）。

Subject to Sensei stockholder approval, each share of Series B non-voting convertible preferred stock will automatically convert into 1,000 shares of common stock, subject to certain beneficial ownership limitations set by each holder. As a result of the transactions, equityholders of Sensei immediately prior to the acquisition will own approximately 4.9% of Sensei’s common stock, equityholders of Faeth immediately prior to the acquisition will own approximately 40.8% of Sensei’s common stock and investors in the private placement financing will own approximately 54.3% of Sensei’s common stock, in each case, calculated on a fully-diluted, as-converted-to-common-basis (and without giving effect to any beneficial ownership limitations) using the treasu.

在获得Sensei股东批准的前提下，每股B系列无投票权可转换优先股将自动转换为1000股普通股，但需遵守每位持有人设定的某些有益所有权限制。交易完成后，在收购前Sensei的股东将持有Sensei约4.9%的普通股，Faeth的股东在收购前将持有Sensei约40.8%的普通股，而私募融资中的投资者将持有Sensei约54.3%的普通股。以上每种情况均按完全稀释、转换为普通股基础计算（且不考虑任何有益所有权限制），并使用库存。

The acquisition was approved by the Board of Directors of Sensei and the Board of Directors and stockholders of Faeth. The closings of the transactions were not subject to the approval of Sensei’s stockholders. The approval of Sensei’s stockholders is required under the terms of the Series B non-voting convertible preferred stock in order for the Series B non-voting convertible preferred stock to be converted into shares of Sensei common stock, and Sensei is required to hold a stockholder meeting for such vote.

该收购已获得Sensei董事会和Faeth董事会及股东的批准。交易的完成无需Sensei股东的批准。然而，根据B系列非投票可转换优先股的条款，要将其转换为Sensei普通股，必须获得Sensei股东的批准，且Sensei须召开股东大会进行相关投票。

On an as-converted basis and after accounting for these transactions (and without giving effect to any beneficial ownership limitations), the total number of shares of Sensei common stock (including shares underlying the Series B non-voting convertible preferred stock) will be approximately 26,304,468..

在转换基础上并考虑到这些交易后（且不考虑任何有益所有权限制），Sensei普通股的总股数（包括B系列无投票权可转换优先股对应的股票）将约为26,304,468股。

Lucid Capital Markets is serving as financial advisor to Sensei. Sidley Austin LLP is serving as legal counsel to Sensei. Leerink Partners is serving as the exclusive placement agent for the concurrent financing. Cantor and Citi are also serving as capital markets advisors to Sensei for the concurrent financing.

Lucid Capital Markets 担任Sensei的财务顾问。Sidley Austin LLP 担任Sensei的法律顾问。Leerink Partners 担任此次同时进行的融资的独家配售代理。Cantor 和 Citi 也担任Sensei的资本市场顾问，参与此次同时进行的融资。

Cooley LLP is serving as legal counsel to Faeth..

科利律师事务所（Cooley LLP）担任法思（Faeth）的法律顾问。

Conference Call and Webcast Details

电话会议和网络直播详情

The company will host a conference call and webcast today, February 18, 2026, at 8:30 a.m. ET to discuss the acquisition and financing, as well as Faeth’s approach and pipeline assets. To access the call, please click dial-in access. Once registered, participants will receive a dial‑in number, a unique PIN, and a confirmation email with full details.

公司将于 2026 年 2 月 18 日东部时间上午 8 点 30 分举办电话会议和网络直播，讨论此次收购与融资，以及 Faeth 的方法和管线资产。要接入电话，请点击拨入访问。注册后，参与者将收到拨入号码、唯一 PIN 码以及包含完整详情的确认邮件。

To access the live webcast, please click webcast access. A replay of the webcast presentation will be temporarily archived on the Investors section of the company’s website following the presentation..

要访问现场网络直播，请点击网络直播访问。网络直播结束后，公司网站的投资者关系部分将暂时存档此次演示文稿的重播。

Cautionary Note Regarding Forward-Looking Statements

关于前瞻性陈述的谨慎声明

Certain statements in this press release, other than purely historical information, may constitute 'forward-looking statements' within the meaning of the federal securities laws, including for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995, concerning Sensei, Faeth, the concurrent financing and the acquisition of Faeth by Sensei (the 'Transactions') and other matters.

本新闻稿中的某些陈述，除纯历史信息外，可能构成联邦证券法意义上的“前瞻性陈述”，包括根据1995年美国私人证券诉讼改革法案的安全港条款，涉及Sensei、Faeth、同时进行的融资以及Sensei对Faeth的收购（“交易”）及其他事项。

These forward-looking statements include, but are not limited to, express or implied statements relating to the company’s expectations, hopes, beliefs, intentions or strategies regarding the future including, without limitation, statements regarding: the Transactions, including the closing of the concurrent financing, if any, and the expected effects, perceived benefits or opportunities and related timing with respect thereto; expectations regarding or plans for the company’s pipeline, including its ongoing clinical trials, research and development programs and the expected timing for key milestones; the potential benefits of PIKTOR; and expectations regarding the use of proceeds from the concurrent financing and cash runway expectations therefrom, including such proceeds funding the company through key clinical milestones.

这些前瞻性陈述包括但不限于与公司对未来预期、希望、信念、意图或策略相关的明确或隐含的陈述，其中包括但不限于：关于交易的陈述，包括任何同步融资的完成（如有）及其预期影响、感知到的利益或机会及相关时间；对公司研发管线的预期或计划，包括正在进行的临床试验、研发项目及关键里程碑的预期时间；PIKTOR的潜在益处；以及对同步融资所得款项用途的预期和由此产生的现金跑道预期，包括该等款项将资助公司通过关键临床里程碑。

In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words 'opportunity,' 'potential,' 'milestones,' 'pipeline,' 'can,' 'goal,' 'aim,' 'strategy,' 'target,' 'seek,' 'anticipate,' 'achieve,' 'believe,' 'contemplate,' 'continue,' 'could,' 'estimate,' 'expect,' 'intends,' 'may,' 'might,' 'plan,' 'possible,' 'predict,' 'project,' 'should,' 'will,' 'would' and similar expressions (i.

此外，任何指代预测、预报或其他对未来事件或情况的描述的声明，包括任何潜在假设，均为前瞻性声明。诸如“机会”、“潜力”、“里程碑”、“渠道”、“能够”、“目标”、“目的”、“战略”、“靶向”、“寻求”、“预期”、“实现”、“相信”、“考虑”、“继续”、“可能”、“估计”、“期望”、“意图”、“或许”、“计划”、“可能”、“预测”、“预计”、“应该”、“将”、“会”等词语及类似表达（即。

Investor Contact:

投资者联系人：

Stephanie Ascher, Precision AQ

史蒂芬妮·阿舍，精准AQ

Stephanie.ascher@precisionaq.com

Stephanie.ascher@precisionaq.com

Media Contact:

媒体联系人：

Patrick Schmidt, Consort Partners

帕特里克·施密特，康索特合伙人

senseibio@consortpartners.com

senseibio@consortpartners.com

Source: senseibio.com

来源：senseibio.com